RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Pliant Therapeutics ROA 2024

Pliant Therapeutics ROA

-0.32

Pliant Therapeutics Dividend yield

Ticker

PLRX

ISIN

US7291391057

WKN

A2P4YV

In 2024, Pliant Therapeutics's return on assets (ROA) was -0.32, a -10.44% increase from the -0.35 ROA in the previous year.

Pliant Therapeutics Aktienanalyse

What does Pliant Therapeutics do?

Pliant Therapeutics Inc is a biopharmaceutical company located in South San Francisco, California. The company was founded in 2016 by a group of scientists specializing in the discovery of therapeutics for the treatment of fibrosis and cancer. The history of Pliant Therapeutics Inc begins with the discovery of proteins involved in the development of fibrosis. These proteins, known as integrins, play a key role in tissue repair and regeneration. However, when they are overactive, they can lead to an overproduction of connective tissue, resulting in fibrosis. Pliant Therapeutics Inc aims to develop innovative therapeutics for the treatment of fibrosis and cancer. The company utilizes an innovative business model based on the discovery and development of novel therapeutics targeting the regulation of integrins. The company specializes in various areas. One important focus is the research of therapeutics for the treatment of lung diseases such as idiopathic pulmonary fibrosis (IPF) and asthma. Pliant Therapeutics Inc focuses on the discovery of drugs that inhibit the fibrosis process and improve lung function. Another focus of Pliant Therapeutics Inc is the development of therapeutics for the treatment of connective tissue disorders, such as scleroderma and systemic lupus erythematosus (SLE). The company has also launched a program for the development of therapeutics for the treatment of cancer. Pliant Therapeutics Inc focuses on the discovery of drugs that inhibit tumor growth and improve the effectiveness of cancer drugs. Pliant Therapeutics Inc has several products in the pipeline, including PT004 for the treatment of lung diseases and PT001 for the treatment of scleroderma. PT004 is an inhalable drug that aims to inhibit the fibrosis process in the lungs. It is currently in Phase 2 of clinical development and has the potential to improve lung function in patients with idiopathic pulmonary fibrosis (IPF) and severe asthma. PT001 is an orally administered drug that targets the treatment of scleroderma. The drug is currently in preclinical development and has the potential to inhibit the fibrosis process in various organs. Overall, Pliant Therapeutics Inc has the potential to play a leading role in the discovery and development of novel therapeutics for the treatment of fibrosis and cancer. The company is well-funded and has an experienced team of scientists and managers specializing in the development of innovative therapeutics. Pliant Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Pliant Therapeutics's Return on Assets (ROA)

Pliant Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Pliant Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Pliant Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Pliant Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Pliant Therapeutics Stock

What is the Return on Assets (ROA) of Pliant Therapeutics this year?

The Return on Assets (ROA) of Pliant Therapeutics is -0.32 undefined this year.

What was the ROA of Pliant Therapeutics compared to the previous year?

The ROA of Pliant Therapeutics has increased by -10.44% compared to the previous year.

What consequences do high ROA have for investors of Pliant Therapeutics?

A high ROA is advantageous for investors of Pliant Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Pliant Therapeutics?

A low ROA can be unfavorable for investors of Pliant Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Pliant Therapeutics affect the company?

An increase in ROA of Pliant Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Pliant Therapeutics impact the company?

A reduction in the ROA of Pliant Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Pliant Therapeutics?

Some factors that can influence the ROA of Pliant Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Pliant Therapeutics important for investors?

The ROA of Pliant Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Pliant Therapeutics take to improve ROA?

To improve ROA, Pliant Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Pliant Therapeutics pay?

Over the past 12 months, Pliant Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pliant Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Pliant Therapeutics?

The current dividend yield of Pliant Therapeutics is .

When does Pliant Therapeutics pay dividends?

Pliant Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pliant Therapeutics?

Pliant Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Pliant Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pliant Therapeutics located?

Pliant Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pliant Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pliant Therapeutics from 5/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/31/2024.

When did Pliant Therapeutics pay the last dividend?

The last dividend was paid out on 5/31/2024.

What was the dividend of Pliant Therapeutics in the year 2023?

In the year 2023, Pliant Therapeutics distributed 0 USD as dividends.

In which currency does Pliant Therapeutics pay out the dividend?

The dividends of Pliant Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Pliant Therapeutics

Our stock analysis for Pliant Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pliant Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.